Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
NCT03334487
Withdrawn
A single-arm, open-label study to assess the overall safety of rovalpituzumab tesirine in participants with relapsed or refractory delta-like protein 3 (DLL3) expressing small cell lung cancer by evaluating the frequency of high grade (\>= Grade 3) select treatment-emergent adverse events (TEAEs).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/21/2018
Locations: Ironwood Cancer & Res Ctr /ID# 171335, Chandler, Arizona +59 locations
Conditions: Small Cell Lung Cancer
Register for Updates
Facet Versus Trigger Point Injections for Chronic Neck Pain
NCT01808586
Completed
A) Background Chronic neck pain is a significant and common issue which is difficult to treat. Tight bands of muscle (trigger points) can be a source of chronic neck pain and they are sometimes injected to manage chronic neck pain. However, these injections seldom lead to significant, long-lasting relief. In some cases, these trigger points may originate from injury or damage to a specific joint in the neck (the facet joint). Treatment of this joint with cortisone injection may lead to improved... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
12/13/2018
Locations: St. Joseph's Hospital / Parkwood Hospital, London, Ontario
Conditions: Neck Pain
Register for Updates
PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial
NCT02374060
Completed
To evaluate the relative efficacy of three commonly utilized regional corticosteroids for the regional treatment of uveitic macular edema: periocular triamcinolone acetonide; intravitreal triamcinolone acetonide; intravitreal dexamethasone implant. The primary efficacy measure will be percent change in central subfield thickness as measured by OCT at 8 weeks. Participants will continue in the study for 24 weeks in order to evaluate relative effects of the 3 treatment strategies on the duration o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/06/2018
Locations: Jules Stein Eye Institute, UCLA, Los Angeles, California +25 locations
Conditions: Macular Edema, Uveitis
Register for Updates
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study
NCT01311687
Completed
The purpose of this study is to compare efficacy and safety of pomalidomide in combination with low-dose dexamethasone versus high-dose dexamethasone in subjects with refractory or relapsed and refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/25/2018
Locations: Mayo Clinic, Rochester, Minnesota +93 locations
Conditions: Multiple Myeloma
Register for Updates
A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma
NCT01672736
Terminated
This is a multi-center, open-label, non-randomized study. Patients will receive ASP7487 (OSI-906) in combination with bortezomib and dexamethasone. Phase 1 involves dose escalation of the combination, whereas Phase 2 involves the expansion of ASP7487 (OSI-906) combined with bortezomib and dexamethasone at the MTD to establish the ORR. This trial will accrue patients with relapsed or relapsed/refractory MM - a disease state for which bortezomib is approved to treat by the FDA and Health Canada. T... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/12/2018
Locations: Emory University Winship Cancer Institute, Atlanta, Georgia +5 locations
Conditions: Multiple Myeloma
Register for Updates
Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema
NCT02684084
Terminated
This is a 24-week, prospective, multi-center, open-label, randomized, investigator-initiated pilot study to explore the effects of RBZ (0.5 mg) plus DEX implant (0.7 mg) PRN combination therapy (n = 30) vs. DEX implant PRN monotherapy (n = 30) in pseudophakic eyes with center-involved DME that have demonstrated prior incomplete response to 3-6 anti-VEGF treatments.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/17/2018
Locations: Toronto Retina Institue, Toronto, Ontario +1 locations
Conditions: Diabetic Macular Edema
Register for Updates
Intravenous Dexamethasone to Increase the Analgesic Duration of Interscalene Block
NCT02412657
Completed
Interscalene brachial plexus block provides excellent but time limited analgesia. Intravenous dexamethasone increases the analgesic duration of a single-shot interscalene block with ropivacaine for shoulder arthroscopic surgery. We want to evaluate the effect of two different doses (dexamethasone 10 mg i.v. vs 4 mg i.v. vs placebo) on the analgesic duration of a single-shot inter scalene block. Our study hypothesis is that dexamethasone 4 mg i.v. is equivalent to dexamethasone10 mg i.v. in prolo... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/16/2018
Locations: Hopital Pierre-Boucher, Longueuil, Quebec +2 locations
Conditions: Pain
Register for Updates
Single Versus Double Injection Costoclavicular Block
NCT03595514
Unknown
In this trial, the objective is to compare single- and double-injection ultrasound-guided costoclavicular blocks. The rationale behind this idea is that a second local anesthetic injection, inside the costoclavicular space, may compensate for the dynamic cord dispersion seen with the single-injection technique. Thus the research hypothesis is that, compared to its single-injection counterpart, a double injection costoclavicular block will result in a shorter onset time.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/14/2018
Locations: Montreal General Hospital, Montreal, Quebec
Conditions: Upper Extremity Injury
Register for Updates
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
NCT01428492
Completed
Phase Ib, open-label study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clinical activity of GSK2110183 dosed in combination with bortezomib and dexamethasone in multiple myeloma (MM) subjects who have failed at least one line of systemic treatment. Part 1 will identify the maximum tolerated dose(s) (MTD) of the combination regimen. Schedule A - GSK2110183 administered once daily with bortezomib (1.3 mg/m2) and dexamethasone (20 mg) given biweekly. Part... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2018
Locations: Novartis Investigative Site, Scottsdale, Arizona +12 locations
Conditions: Multiple Myeloma
Register for Updates
Chalazion Conservative Treatment Trial
NCT01230593
Completed
An eyelid stye, or chalazion, is the most common eyelid ailment, and is caused by the blockage of one of the oil secreting glands of the eyelid (meibomian glands). This leads to a typically painful, swollen, and red eyelid bump that lasts from days to weeks and months. The chalazion may cause tearing, pressure on the cornea, and irritation, all of which contribute to its morbidity. There are many anecdotal first line treatments for this condition, including warm compresses to the eyelid, topical... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/09/2018
Locations: Elmhurst Hospital Center, Elmhurst, New York +2 locations
Conditions: Chalazion Unspecified Eye, Unspecified Eyelid, Chalazion Left Eye, Unspecified Eyelid, Chalazion Right Eye, Unspecified Eyelid, Chalazion Both Eyes
Register for Updates
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
NCT01478048
Completed
The purpose of the study is to determine whether the addition of Elotuzumab to Bortezomib/ Dexamethasone will prolong the time before myeloma worsens \[progression free survival (PFS)\].
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/20/2018
Locations: Compassionate Cancer Res Grp, Corona, California +76 locations
Conditions: Multiple Myeloma
Register for Updates
OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab
NCT01243086
Completed
In the Western World, Age Related Macular Degeneration (ARMD) is a leading cause of blindness. This disease was once thought to be a natural part of aging, but recent research has introduced effective treatments. ARMD is related to the body initiating an immune response in the eye, as if responding to an infection. Vision is impacted as ocular tissue becomes inflamed and new blood vessels form at the back of the eye, a process called angiogenesis. In the more severe wet form of ARMD, blood and f... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
04/05/2018
Locations: St. Joseph's Healthcare Hamilton Regional Eye Centre, Hamilton, Ontario
Conditions: Wet Macular Degeneration
Register for Updates